US Patent

US9492316 — Prostamide-containing intraocular implants and methods of use thereof

Formulation · Assigned to Allergan Inc · Expires 2034-10-31 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects prostamide-containing intraocular implants that reduce intraocular pressure in the eye for a sustained period.

USPTO Abstract

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.

Drugs covered by this patent

Patent Metadata

Patent number
US9492316
Jurisdiction
US
Classification
Formulation
Expires
2034-10-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.